• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The role of mechanical circulatory support as destination therapy for ambulatory heart failure.
Glob Cardiol Sci Pract. 2016 Sep 30;2016(3):e201624. doi: 10.21542/gcsp.2016.24.
2
Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial.随机试验：左心室辅助装置作为终末期心力衰竭患者的治疗目标与指南指导的药物治疗的比较。SWEdish evaluation of left Ventricular Assist Device（SweVAD）试验的原理和设计。
Eur J Heart Fail. 2020 Apr;22(4):739-750. doi: 10.1002/ejhf.1773. Epub 2020 Feb 26.
3
Left ventricular assist devices: an evidence-based analysis.左心室辅助装置：基于证据的分析
Ont Health Technol Assess Ser. 2004;4(3):1-69. Epub 2004 Mar 1.
4
Mechanical Ventricular Assistance as Destination Therapy for End-Stage Heart Failure: Has it Become a First Line Therapy?机械心室辅助作为终末期心力衰竭的目标治疗：它已成为一线治疗方法了吗？
Front Surg. 2015 Aug 3;2:35. doi: 10.3389/fsurg.2015.00035. eCollection 2015.
5
A Novel Extracorporeal Continuous-Flow Ventricular Assist System for Patients With Advanced Heart Failure　- Initial Clinical Experience.一种新型体外连续流心室辅助系统治疗晚期心力衰竭患者的初步临床经验。
Circ J. 2020 Jun 25;84(7):1090-1096. doi: 10.1253/circj.CJ-19-1122. Epub 2020 May 28.
6
Bridge-to-decision therapy with a continuous-flow external ventricular assist device in refractory cardiogenic shock of various causes.在各种病因所致难治性心源性休克中使用连续流体外心室辅助装置进行桥接决策治疗。
Circ Heart Fail. 2014 Sep;7(5):799-806. doi: 10.1161/CIRCHEARTFAILURE.113.000271. Epub 2014 Jul 15.
7
INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure.INTERMACS（机械辅助循环支持跨机构注册中心）分析可识别因心力衰竭住院后接受药物治疗的高危门诊患者。
Circ Heart Fail. 2016 Nov;9(11). doi: 10.1161/CIRCHEARTFAILURE.116.003032.
8
Left Ventricular Assist Devices for Destination Therapy: A Health Technology Assessment.用于终末期治疗的左心室辅助装置：一项卫生技术评估
Ont Health Technol Assess Ser. 2016 Feb 8;16(3):1-60. eCollection 2016.
9
Outcomes of children implanted with ventricular assist devices in the United States: First analysis of the Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS).美国植入心室辅助装置儿童的治疗结果：机械循环支持儿科跨机构注册研究（PediMACS）的首次分析。
J Heart Lung Transplant. 2016 May;35(5):578-84. doi: 10.1016/j.healun.2016.01.1227. Epub 2016 Feb 10.
10
Cost-Effectiveness of Ventricular Assist Device Destination Therapy for Advanced Heart Failure in Duchenne Muscular Dystrophy.杜氏肌营养不良症晚期心力衰竭患者心室辅助装置目标治疗的成本效益
Pediatr Cardiol. 2018 Aug;39(6):1242-1248. doi: 10.1007/s00246-018-1889-5. Epub 2018 May 17.

引用本文的文献

1
Current indications for insertion of rotary pumps revisited.
Glob Cardiol Sci Pract. 2016 Sep 30;2016(3):e201625. doi: 10.21542/gcsp.2016.25.

本文引用的文献

1
Pump thrombosis in the Thoratec HeartMate II device: An update analysis of the INTERMACS Registry.Thoratec HeartMate II装置中的泵血栓形成：INTERMACS注册研究的最新分析
J Heart Lung Transplant. 2015 Dec;34(12):1515-26. doi: 10.1016/j.healun.2015.10.024.
2
Seventh INTERMACS annual report: 15,000 patients and counting.国际机械循环辅助装置注册研究（INTERMACS）第七年度报告：15000例患者及仍在增加。
J Heart Lung Transplant. 2015 Dec;34(12):1495-504. doi: 10.1016/j.healun.2015.10.003. Epub 2015 Oct 8.
3
The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report--2015; Focus Theme: Early Graft Failure.国际心肺移植学会登记处：第三十二次成人心脏移植官方报告——2015年；重点主题：早期移植物功能衰竭
J Heart Lung Transplant. 2015 Oct;34(10):1244-54. doi: 10.1016/j.healun.2015.08.003. Epub 2015 Aug 28.
4
Have risk factors for mortality after heart transplantation changed over time? Insights from 19 years of Cardiac Transplant Research Database study.心脏移植后死亡的危险因素随时间有变化吗？来自心脏移植研究数据库19年研究的见解。
J Heart Lung Transplant. 2014 Dec;33(12):1304-11. doi: 10.1016/j.healun.2014.08.014. Epub 2014 Aug 28.
5
Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device.INTERMACS（机械辅助循环支持机构注册研究）分析 HeartMate II 左心室辅助装置中的泵血栓形成。
J Heart Lung Transplant. 2014 Jan;33(1):12-22. doi: 10.1016/j.healun.2013.11.001. Epub 2013 Nov 27.
6
Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation?长期机械循环支持（终末期治疗）：有望与心脏移植相媲美？
J Thorac Cardiovasc Surg. 2012 Sep;144(3):584-603; discussion 597-8. doi: 10.1016/j.jtcvs.2012.05.044. Epub 2012 Jul 15.
7
Third INTERMACS Annual Report: the evolution of destination therapy in the United States.第三届 INTERMACS 年度报告：美国心脏移植终点治疗的演变。
J Heart Lung Transplant. 2011 Feb;30(2):115-23. doi: 10.1016/j.healun.2010.12.001.
8
Long-term use of a left ventricular assist device for end-stage heart failure.终末期心力衰竭患者长期使用左心室辅助装置。
N Engl J Med. 2001 Nov 15;345(20):1435-43. doi: 10.1056/NEJMoa012175.

The role of mechanical circulatory support as destination therapy for ambulatory heart failure.

作者信息

Kirklin James K

机构信息

Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.

出版信息

Glob Cardiol Sci Pract. 2016 Sep 30;2016(3):e201624. doi: 10.21542/gcsp.2016.24.

DOI:10.21542/gcsp.2016.24
PMID:29043271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5642829/
Abstract

Continuous flow technology has dramatically improved patient survival during ventricular assist device (VAD) therapy in recent years. Health-related quality of life is improved by at least two years. Despite remarkable progress in this field, major adverse events during VAD support limit the effectiveness of this therapy and present major barriers to its extension to ambulatory advanced heart failure patients. The pace of progress will depend on improvements in both the adverse event profile and development of semi-quantitative methodology to calculate and display a composite of survival and health-related quality of life.

摘要